Posts tagged ‘PTEN PI3K’
After a hectic ASCO 2012, the next conference we will be attending is The New York Academy of Sciences (NYAS), Inositol Phospholipid Signaling in Physiology and Disease event on June 26 -27, 2012 in New York.
The NYAS often run events that are on a par with the American Association for Cancer Research (AACR), where leading researchers present their early-stage findings to the science community. Cancer signaling pathways are complex and understanding basic science in this area is key to rational drug development and target identification.
The keynote lecture is by Lewis Cantley, who will speak on “Phosphoinositol Signaling and Disease.” Of the many interesting topics from a new product development perspective that will be discussed, a few that caught our attention include:
- Lloyd Trotman, PTEN Activity
- Neil Rosen, Mechanisms of PI3K Inhibition in Cancer
- David Solit, Interrupting the PI3K-AKT-mTOR Pathway in Cancer Therapy
Researchers from Novartis and Gilead will also discuss some of the challenges in clinical development and targeting PI3Kδ in lymphoid malignancies.
If you are interested in the PI3-kinase area for drug development or want to learn more about the where the cutting edge of cancer research is at in this area, then the NYAS event on inositol phospholipid signaling looks well worth attending.
Icarus Consultants is delighted to be a promotional partner with The New York Academy of Sciences for this event, and in return we can offer readers a 15% discount on the cost of meeting registration. Use the special code INOSITOL15 when making your booking – please note this does not apply to existing registrations.
If you can’t make it to New York, Sally Church will be writing about it on Pharma Strategy Blog, unless a budding young scientist attending the meeting would like to write a guest post – if that’s you, then please do contact us and we would be delighted to hear from you!
Update June 28, 2012
The New York Academy of Sciences meeting was well worth attending.
Sally Church, PhD has written about data presented at the meeting on PI3K delta and Bruton’s Tyrosine Kinase (BTK) inhibitors in development for CLL & NHL.
In her Pharma Strategy Blog post, Sally discusses some of the challenges and opportunities for GS-1101 (formerly CAL-101) and ibrutinib.
As reported by Sally Church, PhD on Pharma Strategy Blog today, the tumor suppressor gene PTEN has an important role to play in breast cancer. Sally previously wrote about the role PTEN plays in non-melanoma skin cancer.
In her Pharma Strategy blog post, Sally discusses research from the Institute of Cancer Research (ICR) in London published online first in the new AACR journal, Cancer Discovery.
Researchers looked at genetic changes found in cancer tumor cells and identified the critical genes associated with the growth of specific cancer subtypes, and those that were not. As Sally describes it, “which are drivers and passengers.” This is important if you want to develop a targeted therapy.
This large scale profiling led to the classification of breast cancers into distinct subtypes. In particular the ICR researchers identified possible targets for PTEN-mutated and oestrogen-receptor positive breast cancers.
As Sally notes this approach if successful “could be replicated in other tumor types.”
You can read more on Pharma Strategy Blog about PTEN as a target, and inhibitors in development such as Semafore’s SF1670.